Zaragoza

• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• Clinical Trial to Evaluate the Safety and Appropriateness of Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir A … Ended
  2024-511951-16-00 6 2022-08-30 HIV
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Ended
  2023-509095-42-00 4 2022-07-14 Colorectal cancer
• Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance … Ended
  2024-514293-46-00 4 2022-07-07 Unresectable locally advanced or metastatic urothelial cancer
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended
  2023-508571-37-00 4 2022-04-29 Geographic atrophy (GA) secondary to Age-related Macular Degeneration
• A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patien … Ended
  2024-513229-22-00 4 2022-04-21 Advanced cutaneous melanoma and Advanced mucosal melanoma
• Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended
  2023-508828-35-01 5 2022-03-28 Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom … Ended
  2024-511361-11-00 10 2022-03-25 Advanced dedifferentiated liposarcoma
• ​Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Fir … Ended
  2023-506074-12-00 5 2022-03-22 Metastatic Non-Small Cell Lung Cancer
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended
  2023-509406-30-00 10 2022-01-24 Patients with HER2-overexpressing advanced or metastatic gastric or ga
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 5 2022-01-20 Chronic Obstructive Pulmonary Disease (COPD)
• CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIM … Ended
  2024-513123-17-00 5 2022-01-12 Non-infection uveitis
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Oc … Ended
  2022-502542-28-00 4 2021-12-06 Sickle Cell Disease
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended
  2024-510762-16-00 4 2021-11-30 Metastatic head and neck squamous cell carcinoma (HNSCC)
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended
  2024-519633-35-00 6 2021-10-25 Resectable pancreatic adenocarcinoma with risk factors
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
• Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients with Hom … Ended
  2023-510057-41-00 5 2021-10-06 Patients With Homozygous and Heterozygous Familial Hypercholesterolemi

Showing 457–480 of 527 trials